Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.99, read 2026-11-02
Ethical does not pass the values gate
Price108.71 USD
Fair value116.00
Ethical score10.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup112.57-3.4% to today Markdown gives way to Markup with volume flow in agreement
2026-09-15Read Markdown107.74+0.9% to today Distribution gives way to Markdown after a 6% slide in 4 weeks
2026-08-15Read Distribution114.98-5.5% to today ✓Accumulation gives way to Distribution after an 8% rise in 6 weeks
2026-07-02Read Accumulation105.99+2.6% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
T. Rowe Price holds its Markup at $108.71. Consolidating, no directional conviction, held for 48 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 48 days
Price at the screen
$108.71
Valuation
10.43 trailing · 10.24 forward price to earnings
Values screen
FAIL· score 10.0
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
T. Rowe Price does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TROW's ethical verdict changes
Today TROW does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 3% discount to our $116.00 fair value, moderate competitive moat, 5.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 6.3% discount to the base estimate.
Where our models see it going: fair-value estimate $116.00, with a range of $92.27 to $153.78, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Savings giant trips over its own ethics test
Every monthly contribution into a workplace pension or retail fund travels through an asset manager that still posts a 28 percent profit margin and 19 percent ROE. T. Rowe Price looks steady on paper, yet we pass without hesitation.
The forward multiple of 11.3 times earnings prices in only modest 5 percent revenue growth, and twelve analysts already mark the shares 9 dollars below where they trade today. A moderate moat does little to change the arithmetic when the ethical screen returns a clear fail on business activity grounds.
That single red flag overrides any narrow valuation cushion and keeps the name firmly on the avoid list. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TROW trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$112.57+8.0%Entry 17
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $105.
2026-10-29Markdown$104.20+3.2%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$100.97+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$100.97+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$100.97+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$100.97+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$100.97+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$100.97+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$100.97+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$100.97-4.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (13 analysts) rates it hold, with a mean price target of $106.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
